N/A
Completed N=184
Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Source: ClinicalTrials.gov NCT01468597 ↗Enrolled (actual)
184
Serious AEs
8.7%
Results posted
Jun 2020
Primary outcomePrimary: Calculated Blood Loss — 1996 milliters
Summary
The aim of the study is to evaluate if there is an association between platelet inhibition and surgery-related bleeding in patients undergoing emergent cardiac surgery during dual antiplatelet therapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Calculated Blood Loss |
1996 | — |
| SECONDARY BARC Bleeding |
72 | — |
Eligibility Criteria
Inclusion Criteria
- First time on-pump CABG with or without valve replacement
Exclusion Criteria
- Redo surgery,
- Renal insufficiency needing dialysis,
- Concomitant medication with warfarin,
- Preoperative fibrinogen < 150 mg%
Data sourced from ClinicalTrials.gov (NCT01468597). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.